185 related articles for article (PubMed ID: 14556932)
21. Characterization of a novel lymph node metastasis model from human colonic cancer and its preclinical use for comparison of anti-metastatic efficacy between oral S-1 and UFT/ LV.
Ito Y; Nakanishi H; Kodera Y; Hirai T; Nakao A; Kato T
Cancer Sci; 2010 Aug; 101(8):1853-60. PubMed ID: 20500514
[TBL] [Abstract][Full Text] [Related]
22. [Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase].
Ishida H; Yamada H; Shirakawa K; Nakada H; Ohsawa T; Takeuchi I; Okada N; Yokoyama M; Inokuma S; Suzuki T; Odaka A; Hoshino T; Murata N; Hashimoto D; Itoyama S; Mori T; Matsumoto Y; Miura T
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1621-6. PubMed ID: 14619479
[TBL] [Abstract][Full Text] [Related]
23. Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer.
Ichikura T; Tomimatsu S; Okusa Y; Yahara T; Uefuji K; Tamakuma S
Cancer Chemother Pharmacol; 1996; 38(5):401-5. PubMed ID: 8765432
[TBL] [Abstract][Full Text] [Related]
24. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer.
Miyamoto S; Boku N; Ohtsu A; Yoshida S; Ochiai A; Okabe H; Fukushima M
Int J Oncol; 2000 Oct; 17(4):653-8. PubMed ID: 10995874
[TBL] [Abstract][Full Text] [Related]
26. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
[TBL] [Abstract][Full Text] [Related]
27. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.
Miyoshi T; Kondo K; Toba H; Yoshida M; Fujino H; Kenzaki K; Sakiyama S; Takehisa M; Tangoku A
Anticancer Res; 2007; 27(4C):2641-8. PubMed ID: 17695427
[TBL] [Abstract][Full Text] [Related]
28. Effects of UFT on thymidylate synthase and dihydropyrimidine dehydrogenase activities in lung cancer.
Miyamoto H; Morio A; Izumi H; Yamazaki A; Wang Z; Futagawa T; Sonobe S
Anticancer Res; 2003; 23(5b):4153-6. PubMed ID: 14666617
[TBL] [Abstract][Full Text] [Related]
29. Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
Inoue S; Ohtani H; Tsujimoto M; Hori S; Sawada Y
Drug Metab Pharmacokinet; 2007 Jun; 22(3):162-8. PubMed ID: 17603216
[TBL] [Abstract][Full Text] [Related]
30. [Level of inhibition of thymidylate synthase activity and 5-fluorouracil in tumor tissues after administration of UFT or tegafur].
Suzuki M; Sekiguchi I; Tamada T; Nishida M
Nihon Gan Chiryo Gakkai Shi; 1989 Jul; 24(7):1399-404. PubMed ID: 2530293
[TBL] [Abstract][Full Text] [Related]
31. Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma.
Hisamitsu K; Tsujitani S; Yamaguchi K; Fukuda K; Konishi I; Kaibara N
Anticancer Res; 2004; 24(4):2495-501. PubMed ID: 15330204
[TBL] [Abstract][Full Text] [Related]
32. Oral DPD-inhibitory fluoropyrimidine drugs.
Diasio RB
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
[TBL] [Abstract][Full Text] [Related]
33. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo.
Fukushima M; Sakamoto K; Sakata M; Nakagawa F; Saito H; Sakata Y
Oncol Rep; 2010 Nov; 24(5):1307-13. PubMed ID: 20878125
[TBL] [Abstract][Full Text] [Related]
34. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
35. Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR.
Fujiwara H; Terashima M; Irinoda T; Takagane A; Abe K; Kashiwaba M; Oyama K; Takahashi M; Maesawa C; Saito K; Takechi T; Fukushima M
Jpn J Cancer Res; 2002 Dec; 93(12):1342-50. PubMed ID: 12495474
[TBL] [Abstract][Full Text] [Related]
36. [Support of TS-1, 5-FU preparation containing potent DPD inhibitor by determination of urinary uracil/serum 5-FU clearance].
Morimoto S; Shono Y; Tsuji T; Makihara K; Kawato N; Hachino Y; Mishima H; Tsujinaka T; Tabuse K
Gan To Kagaku Ryoho; 2003 Dec; 30(13):2083-9. PubMed ID: 14712769
[TBL] [Abstract][Full Text] [Related]
37. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats.
Takechi T; Nakano K; Uchida J; Mita A; Toko K; Takeda S; Unemi N; Shirasaka T
Cancer Chemother Pharmacol; 1997; 39(3):205-11. PubMed ID: 8996521
[TBL] [Abstract][Full Text] [Related]
38. High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.
Kuramochi H; Hayashi K; Uchida K; Nakajima G; Hatori T; Danenberg KD; Danenberg PV; Yamamoto M
Cancer Chemother Pharmacol; 2008 Dec; 63(1):85-9. PubMed ID: 18309485
[TBL] [Abstract][Full Text] [Related]
39. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
40. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
Noro R; Miyanaga A; Minegishi Y; Okano T; Seike M; Soeno C; Kataoka K; Matsuda K; Yoshimura A; Gemma A
Cancer Sci; 2010 Jun; 101(6):1424-30. PubMed ID: 20384633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
